▲ +191.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is $34.63, with a high forecast of $36.00 and a low forecast of $33.25. The average price target represents a 191.19% upside from the last price of $11.89.
The current consensus among 2 polled investment analysts is to buy stock in HLS Therapeutics.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and Barbados. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.